Mural Oncology Showcases Innovations in Immuno-Oncology Research
Mural Oncology's Upcoming Presentations at SITC
Mural Oncology plc (NASDAQ: MURA), a prominent player in clinical-stage immunotherapy, is excited to announce its participation in the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) where groundbreaking advancements in their research will be showcased. This prestigious annual event will be held in Houston from November 6-10.
The company is poised to unveil critical findings from its phase 1/2 ARTISTRY-3 study, which explores the pharmacodynamics involved in administering nemvaleukin, Mural's uniquely engineered interleukin-2 (IL-2), at less frequent intervals. The presentation also includes compelling data consolidating their two preclinical programs targeting IL-18 and IL-12.
Poster Presentation Details
Mural Oncology's poster presentations will provide in-depth insights and findings in three distinct areas:
- Title: Tumor microenvironment pharmacodynamic effect of nemvaleukin less frequent intravenous dosing in multiple solid tumors: results from the phase 1/2 ARTISTRY-3 study
Abstract Number: 217
Presentation Date: Friday, Nov. 8 - Title: Preclinical efficacy and immune activity of half-life extended IL-18 fusion proteins resistant to IL-18BP suppression
Abstract Number: 1340
Presentation Date: Saturday, Nov. 9 - Title: Modulation of IL-12p70 exposure and activity following sequential administration of tumor targeted self-assembling split IL-12 subunits
Abstract Number: 1300
Presentation Date: Saturday, Nov. 9
Innovative Approach to Immunotherapy
Mural Oncology is revolutionizing cancer treatment through its innovative protein engineering platform, which focuses on combining the nuances of cytokine biology with cutting-edge immune modulation. This approach is designed to not only enhance the efficacy but also to minimize adverse effects often associated with traditional immunotherapies.
The cornerstone of their research is nemvaleukin, which is currently being tested in potentially registrational trials among patients with platinum-resistant ovarian cancer and mucosal melanoma, with peak data expected in the near term.
The Potential of IL-18
The IL-18 program at Mural Oncology represents a significant leap forward. While IL-18 is a potent immune-activating cytokine, its effectiveness has previously been limited by the presence of IL-18 binding protein (IL-18BP). By utilizing a novel engineering approach, Mural has developed variants of IL-18 that do not bind to IL-18BP, therefore bolstering its availability and action in the body.
This new formulation also involves attaching scaffolds to IL-18, effectively extending its half-life in circulation. The company aims to nominate a development candidate for the IL-18 program soon and is looking forward to filing an Investigational New Drug (IND) submission by the end of 2025.
Pioneering the IL-12 Pathway
Similarly, Mural is forging new paths with its approach to IL-12, a cytokine recognized for its strong pro-inflammatory properties, albeit with considerable toxicity. To lessen this risk, Mural Oncology has innovatively split the IL-12p70 heterodimer into inactive forms that are separately combined with antibody fragments. This allows for a precise delivery to tumor sites while avoiding systemic exposure.
Preclinical results suggest that this strategy helps sustain therapeutic concentrations within tumors while minimizing side effects. The objective is to have a capable candidate for the IL-12 program named by year's end.
Commitment to Advancing Cancer Treatment
Mural Oncology's mission is underscored by a commitment to redefine the landscape of cancer treatment through innovative approaches that not only eliminate tumor cells but also enhance the quality of life for patients. By continually evolving their programs and maintaining a focus on scientific advancement, the company is poised to make significant contributions to the field of immuno-oncology.
Frequently Asked Questions
What is Mural Oncology focused on presenting at SITC?
Mural Oncology will present data regarding nemvaleukin dosing and findings from preclinical research programs on IL-18 and IL-12.
Where will the SITC meeting take place?
The SITC Annual Meeting will be hosted in Houston, Texas.
What is nemvaleukin?
Nemvaleukin is an engineered cytokine designed to improve the therapeutic effects of IL-2 while minimizing associated toxicities.
How does Mural Oncology enhance the effectiveness of IL-18?
Mural's engineering efforts focus on avoiding IL-18BP binding and extending IL-18's half-life for enhanced therapeutic potential.
What advantages does Mural's approach to IL-12 offer?
By splitting IL-12 into inactive units and targeting tumors directly, Mural aims to significantly reduce systemic toxicity while maintaining tumor efficacy.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Carvana Expands Operations with New Megasite in Las Vegas
- Kraft Heinz Set to Announce Financial Results for Q3 2024
- Lincoln Financial's Latest Insights on Investor Trends
- VSS Capital Partners Strengthens Presence with Treya Investment
- Exciting New Compensation Hub Launch for Oil Pollution Victims
- How Online Reviews Are Shaping Rental Decisions Today
- Impact BioMedical Sees Strong Investor Confidence in IPO
- Impact of Seoul Stepping Stone Income on Households and Welfare
- Exploring Growth in the Managed Network Services Sector
- Joining Forces: MAI Capital Management Expands with Halpern
Recent Articles
- ViiV Healthcare Expands Access to Long-Acting HIV Prevention
- Foremost Clean Energy Partners with Denison Mines for Uranium Exploration
- Judo Bio Advances Gene Therapy Research for Kidney Treatment
- Chris Akrimi's New Role at NuORDER by Lightspeed Enhances Growth
- GXO Logistics Plans Earnings Call for Third Quarter 2024
- Oak Hill Bio Welcomes New Executive Leadership and Board Members
- Perspective Therapeutics Engages in Key Oncology Events Ahead
- Energy Recovery Announces Upcoming Financial Results and Webinar
- Generations Bancorp NY, Inc. Joins OTCQX for Enhanced Trading
- Consensus Cloud Solutions Plans Exciting Q3 Earnings Call
- Gray Media Expands Reach with New Local News Live Apps
- BPGbio Teams with Oxford University to Propel Protein Research Forward
- Rubicon Organics Unveils Comprehensive Sustainability Report
- Scholar Rock Celebrates Phase 3 Success for SMA Treatment
- NIU Technologies Unveils KQi 100F Electric Scooter at Expo
- Judo Bio Marks $100M Financing and Welcomes Rajiv Patni as CEO
- Virios and Wex Join Forces to Launch Dogwood Therapeutics
- Laser Photonics Expands to 50,000 sq. ft. Facility for Growth
- Blue Owl Capital's Strategic Move to Enhance Digital Infrastructure
- Chimney and Jack Henry Join Forces to Enhance Homeowner Engagement
- New Era of Flavor: Clark Foods Launches in the U.S. Market
- Leadership Expansion for Vantage Data Centers in APAC Region
- Welltower Sets Earnings Release Date for Q3 2024 Results
- Transforming Audits: The Role of AI and Human Expertise
- Situ Ve Promotes Respect and Empathy in Romantic Relationships
- Jetcraft Strengthens EMEA Sales Team with New Director Role
- Powerfleet Invites Investors to Day of Insights and Growth
- Kinaxis Strengthens Ono Pharmaceutical's Supply Chain Strategy
- Streamlining IT Procurement: SysAid Launches on AWS Marketplace
- Mason Capital Management Consortia's Strategic Acquisition of CB&I
- EVERSANA Strengthens Global Presence with New Office in Berlin
- Dundee Precious Metals Reports Robust Production Figures
- Capital Square Achieves Remarkable 136.42% Return on Investment
- Global Markets Update: Insights into Recent Trends and Movements
- Five Star Franchising Celebrates Success with Top Ten Ranking
- Veralto Strengthens Food Safety Solutions with TraceGains Purchase
- AerCap Achieves Major Milestones in Q3 with $10.5 Billion Financing
- ROSHI Insights: Future of Digital Lending and Growth Trends
- Tint World® Celebrates Achievement with Franchise Times Top 400
- Creekside Behavioral Health Celebrates Six Years of Care
- Enbridge and Microsoft Partner for AI Innovations in Energy Sector
- Glassbeam Partners with Veterans Health Administration for Better Care
- Harts Plumbers Partners with Seahawks to Enhance Fan Experience
- Insight into Copper Demand Amidst Electric Vehicle Evolution
- Discover Magewell's Latest Enhancements for Streaming Ease
- Apollo's $3.6 Billion Purchase of Barnes Group Explained
- Albemarle Corporation's Strategic Moves to Enhance Efficiency
- Keeper Security's Cybersecurity Action Month: Focus on Phishing
- Roth/MKM Affirms Buy Rating as Hasbro Prepares for Growth
- The Life-Changing Power of Plasma Donation Awareness Campaign